New guidelines aim to make prostate cancer screening smarter, not just more frequent
NCT ID NCT04782713
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested new guidelines for PSA screening to help doctors decide when to start and stop screening, how often to repeat it, and when to refer for biopsy. Researchers also provided patient navigation for men with elevated PSA levels. The goal was to see if these steps could reduce unnecessary biopsies and focus on cancers that truly need treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to smarter, safer PSA screening that catches dangerous prostate cancers while avoiding unnecessary biopsies.
- What could go wrong
- This was a small, completed study with only 49 participants, so results may not apply to larger or more diverse populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mile Square Health Center
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?